Semax vs Bremelanotide (PT-141)

Semax and bremelanotide are both short synthetic peptides related to hormone biology, but their studies ask different questions. Semax reports concern brain signaling and neurological illness; bremelanotide trials concern desire and related distress in premenopausal women with hypoactive sexual desire disorder, meaning persistent low desire that causes distress. No selected trial compares them for memory, stroke recovery or sexual symptoms.

Research reviewed 2026-10-15. Educational information only.

An ACTH-related sequence and a melanocortin agonist have different research aims

Semax is the seven-amino-acid sequence Met-Glu-His-Phe-Pro-Gly-Pro, built from an ACTH-related segment and a Pro-Gly-Pro tail. ACTH is a pituitary hormone, but sequence ancestry does not establish the same hormonal action for the shorter peptide. The rat work examined brain-derived neurotrophic factor, or BDNF, and its receptor TrkB in the hippocampus, a brain region involved in learning. BDNF helps regulate nerve-cell survival and connections; an increase in this protein is a biological measurement rather than a direct measure of human cognition. Dolotov and colleagues (2006).

Bremelanotide, also called PT-141, is a cyclic melanocortin receptor agonist. Its approved acetate injection was studied for acquired, generalized hypoactive sexual desire disorder in premenopausal women. The label identifies receptor activity but states that the exact mechanism of benefit in HSDD remains unknown. Neither a hormone-related sequence nor a general claim of activity in the brain makes the two peptides substitutes for one another.

The main differences

The Semax stroke reports describe recovery, with substantial design gaps

An older acute-stroke report compared 30 Semax-treated patients with 80 patients receiving conventional therapy after strokes of similar severity and location. The authors described faster regression of neurological problems, particularly motor deficits, with Semax added to intensive care. The accessible abstract does not provide numerical clinical effect sizes, uncertainty intervals or enough allocation and blinding information to establish a reliable causal estimate. Gusev and colleagues (1997).

The result is consequently useful as a reported clinical observation in acute brain injury. It does not tell us whether healthy adults remember more, whether benefit persists with current stroke care, or whether Semax changes sexual desire. Treatment of an injured brain and enhancement of healthy performance would require separate patient populations and outcomes.

Brain imaging and animal proteins are supporting measurements

In 24 healthy volunteers, 14 received nasal Semax and 10 received placebo. Resting-state functional MRI was performed before exposure and 5 and 20 minutes afterward. Researchers detected a larger medial-frontal component of the default-mode network in the Semax group. This network is a pattern of correlated activity seen while a person is resting. A larger detected component does not mean the anatomical brain grew, and the experiment did not demonstrate better memory, concentration or daily function. Lebedeva and colleagues (2018).

In the separate rat study, nasal Semax was associated with a maximum 1.4-fold increase in hippocampal BDNF protein and a 1.6-fold increase in TrkB phosphorylation, a chemical change associated with receptor activation. The animals also made more conditioned avoidance responses. This supplies a possible connection between signaling and learned behavior in rats, while leaving a human cognitive benefit to be measured directly. Dolotov and colleagues (2006).

The motor-neuron-disease report separates quality of life from function

A 27-person Semax report in motor-neuron disease described an open-label study in sequential groups, despite being indexed as a randomized controlled trial. The authors reported no influence on the course of partial denervation or the clinical functional estimates. Denervation means that muscle fibers have lost their nerve supply; needle electrical recordings helped follow that process. The abstract does not provide a numerical effect estimate or a clearly defined concurrent control. Serdiuk and colleagues (2007).

Overall quality-of-life scores improved through emotional state and motivation, with the largest reported response on day 10. This subjective observation can matter to patients while remaining a different outcome from slowing functional deterioration. The report therefore does not support a general conclusion that every neurological measurement improved with Semax.

Bremelanotide has two controlled HSDD trials, with narrower conclusions than performance enhancement

The two 24-week RECONNECT trials randomized 1,267 premenopausal women; 1,247 entered the safety population and 1,202 the main efficacy analysis. Women had low desire that developed after previously normal desire, occurred across situations and caused distress. Compared with placebo, pooled desire scores improved by 0.35 points and distress about low desire fell by 0.33 points, both P<0.001. The number of satisfying sexual events did not increase more than with placebo (P=0.630). Kingsberg and colleagues (2019).

These replicated symptom results support a defined indication, rather than a broad claim of improved sexual performance. More women withdrew from bremelanotide than placebo, and missing outcomes were analyzed by carrying the last observation forward. The longer open-label follow-up involved the same cohorts; it adds observation time without becoming another independent placebo-controlled test. Semax’s stroke, imaging and motor-neuron-disease reports did not measure these HSDD outcomes.

The route and tested formulation define what is known about exposure and harm

The Vyleesi label reports a mean terminal elimination half-life of about 2.7 hours after subcutaneous administration, with a range of 1.9–4.0 hours. The selected Semax clinical reports and FDA review do not establish a comparable human intact-peptide concentration-time study. A response 5 or 20 minutes after nasal administration is a measurement schedule, not a half-life or proof of a particular brain concentration. The FDA review also notes inconsistent form reporting and distinguishes the free peptide from acetate and modified products sold under related names.

Nausea occurred in 40.0% of bremelanotide recipients versus 1.3% with placebo in the phase 3 safety population. Vyleesi can temporarily raise blood pressure and slow heart rate, and it can produce pigment changes that may persist. Uncontrolled hypertension and known cardiovascular disease are contraindications. These risks are documented for the medicinal formulation; the label also identifies effects on stomach emptying and oral naltrexone exposure.

Semax has less complete clinical harms reporting in the selected publications. FDA’s 2026 staff review states that neither Semax free base nor Semax acetate is a component of an FDA-approved drug and describes missing human safety information. Its compounding-risk page identifies possible immune responses related to aggregation and peptide impurities. These are safety concerns and information gaps, without a comparative event rate against bremelanotide. The staff briefing is an evaluation for compounding deliberations, not approval of a drug.

No common clinical outcome connects these treatments

Bremelanotide has the clearer controlled evidence for the specific HSDD population studied. Semax’s published observations concern other settings, with varying designs and incomplete access to clinical methods. A more developed trial program for one indication does not show that bremelanotide treats neurological illness, and Semax brain activity does not establish an effect on sexual symptoms. A useful comparison therefore asks what each study measured and whether that outcome matches the proposed use.

Frequently asked questions

Profiles and related reading

References

1. Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, Dubynina EV, Novosadova EV, Andreeva LA, Alfeeva LY, Kamensky AA, Grivennikov IA, Myasoedov NF, Engele J. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain research. 2006;1117(1):54–60. doi:10.1016/j.brainres.2006.07.108. PMID:16996037.

   In rats, nasal Semax increased brain-derived neurotrophic factor (BDNF), a protein involved in nerve-cell survival and adaptation, and activation of its receptor TrkB in the hippocampus, with more conditioned avoidance responses. These are animal molecular and behavioral measurements.

2. Gusev EI, Skvortsova VI, Miasoedov NF, Nezavibat'ko VN, Zhuravleva EIu, Vanichkin AV. [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 1997;97(6):26–34. PMID:11517472.

   An older acute-stroke report compared 30 Semax-treated patients with 80 conventional-care controls and described faster neurological recovery, particularly motor recovery. The accessible abstract lacks numerical effects and allocation details.

3. Lebedeva IS, Panikratova YR, Sokolov OY, Kupriyanov DA, Rumshiskaya AD, Kost NV, Myasoedov NF. Effects of Semax on the Default Mode Network of the Brain. Bulletin of experimental biology and medicine. 2018;165(5):653–656. doi:10.1007/s10517-018-4234-3. PMID:30225715.

   In 24 healthy volunteers, nasal Semax was followed by a larger detected medial-frontal component of a resting-state brain network than placebo. This was an imaging measurement rather than a test of memory or clinical recovery.

4. Serdiuk AV, Levitskiĭ GN, Miasoedov NF, Skvortsova VI. [The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2007;107(4):29–39. PMID:18379501.

   An open-label report in 27 people with motor-neuron disease found no influence on the measured denervation course or clinical functional estimates, while reporting better emotional and motivational quality-of-life scores.

5. Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics and gynecology. 2019;134(5):899–908. doi:10.1097/AOG.0000000000003500. PMID:31599840.

   Two separate randomized trials in premenopausal women found improved desire and related distress with injected bremelanotide versus placebo. Satisfying-event counts did not improve more than placebo; withdrawal and nausea were more frequent.

6. Cosette Pharmaceuticals, Inc. VYLEESI (bremelanotide injection): Full prescribing information. DailyMed. Updated November 13, 2025; accessed October 15, 2026.

   The approved subcutaneous bremelanotide acetate formulation is indicated for acquired, generalized hypoactive sexual desire disorder: distressing low desire that developed after previously normal desire and occurs across situations in premenopausal women after specified alternative causes are excluded. The label defines cardiovascular contraindications, nausea and pigment changes.

7. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. FDA Briefing Document: Semax-Related Bulk Drug Substances (Semax free base and Semax acetate). Pharmacy Compounding Advisory Committee, July23–24,2026.

   The official review identifies the ACTH-related heptapeptide and distinguishes forms sold under the Semax name. Neither free base nor acetate is a component of an FDA-approved drug; human exposure and clinical-safety gaps remain.

8. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Current agency webpage accessed October15,2026.

   FDA identifies potential immune-response and peptide-impurity concerns for compounded Semax and describes insufficient human safety information for the proposed routes.